IL209892A0 - Isoindolone derivatives as mek kinase inhibitors and methods of use - Google Patents

Isoindolone derivatives as mek kinase inhibitors and methods of use

Info

Publication number
IL209892A0
IL209892A0 IL209892A IL20989210A IL209892A0 IL 209892 A0 IL209892 A0 IL 209892A0 IL 209892 A IL209892 A IL 209892A IL 20989210 A IL20989210 A IL 20989210A IL 209892 A0 IL209892 A0 IL 209892A0
Authority
IL
Israel
Prior art keywords
methods
kinase inhibitors
mek kinase
isoindolone derivatives
isoindolone
Prior art date
Application number
IL209892A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41128054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL209892(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL209892A0 publication Critical patent/IL209892A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
IL209892A 2008-07-01 2010-12-09 Isoindolone derivatives as mek kinase inhibitors and methods of use IL209892A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7743208P 2008-07-01 2008-07-01
PCT/US2009/049449 WO2010003022A1 (en) 2008-07-01 2009-07-01 Isoindolone derivatives as mek kinase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
IL209892A0 true IL209892A0 (en) 2011-02-28

Family

ID=41128054

Family Applications (1)

Application Number Title Priority Date Filing Date
IL209892A IL209892A0 (en) 2008-07-01 2010-12-09 Isoindolone derivatives as mek kinase inhibitors and methods of use

Country Status (16)

Country Link
US (1) US8492427B2 (enExample)
EP (1) EP2307364B1 (enExample)
JP (1) JP5615274B2 (enExample)
KR (1) KR20110028376A (enExample)
CN (1) CN102137843A (enExample)
AU (1) AU2009266953A1 (enExample)
BR (1) BRPI0910200A2 (enExample)
CA (1) CA2727252A1 (enExample)
CL (1) CL2010001637A1 (enExample)
ES (1) ES2426096T3 (enExample)
IL (1) IL209892A0 (enExample)
MX (1) MX2010014565A (enExample)
PE (1) PE20110424A1 (enExample)
RU (1) RU2495028C2 (enExample)
WO (1) WO2010003022A1 (enExample)
ZA (1) ZA201008962B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2598660B1 (en) 2010-07-26 2017-03-15 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
CA2806734A1 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
CA2890238A1 (en) 2012-11-02 2014-05-08 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
EP2934572A4 (en) 2012-12-20 2016-11-23 Biomatrica Inc FORMULATIONS AND METHODS FOR STABILIZING PCR REAGENTS
CA2915250A1 (en) 2013-06-13 2015-01-08 Biomatrica, Inc. Cell stabilization
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
KR102222569B1 (ko) * 2013-10-25 2021-03-05 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 피리딘의 케톤 유도체의 제조 방법 및 제약 용도
RS59007B1 (sr) 2014-02-03 2019-08-30 Vitae Pharmaceuticals Llc Dihidropirolopiridinski inhibitori ror-gama
CN103922992B (zh) * 2014-04-25 2015-09-02 温州大学 一种抗癌活性吲哚酮衍生物、合成方法及其用途
CN113826612B (zh) 2014-06-10 2022-11-22 生物马特里卡公司 在环境温度下稳定凝血细胞
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
EA031967B1 (ru) 2014-10-14 2019-03-29 Вайтаи Фармасьютиклз, Инк. ДИГИДРОПИРРОЛОПИРИДИНОВЫЕ ИНГИБИТОРЫ ROR-γ
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
CN104860869B (zh) * 2015-04-03 2017-11-03 北京大学 具有mek激酶抑制功能的化合物及其制备方法与应用
TN2017000483A1 (en) 2015-05-20 2019-04-12 Amgen Inc Triazole agonists of the apj receptor.
WO2017024018A1 (en) 2015-08-05 2017-02-09 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
KR20180086221A (ko) 2015-11-20 2018-07-30 비타이 파마슈티컬즈, 인코포레이티드 Ror-감마의 조절물질
BR112018011639A2 (pt) 2015-12-08 2018-11-27 Biomatrica Inc redução de taxa de sedimentação de eritrócitos
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
KR20180134347A (ko) 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
RU2742234C1 (ru) 2017-06-23 2021-02-03 Систоун Фармасьютикалс Кумариноподобное циклическое соединение в качестве ингибитора мек и его применение
MA49685A (fr) 2017-07-24 2021-04-14 Vitae Pharmaceuticals Llc INHIBITEURS DE ROR gamma
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
US11859252B2 (en) 2017-09-08 2024-01-02 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
EP3735404B1 (en) 2018-01-02 2023-11-29 Seal Rock Therapeutics, Inc. Ask1 inhibitor compounds and uses thereof
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
JP2024521788A (ja) 2021-05-27 2024-06-04 ミラティ セラピューティクス， インコーポレイテッド 併用療法
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA711710B (en) 1970-05-28 1971-12-29 Squibb & Sons Inc Amino derivatives of purazolo-pyridine carboxylic acids and esters
US3736326A (en) 1971-03-29 1973-05-29 Squibb & Sons Inc Isoxazolopyridine carboxylic acids and esters
US4012373A (en) 1972-09-22 1977-03-15 E. R. Squibb & Sons, Inc. Pyrazolo[3',4'-2,3]pyrido[4,5-e]b-benzo-1,5-diazepinones
GB8404586D0 (en) 1984-02-22 1984-03-28 Beecham Group Plc Compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
AU6068600A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
JP2002020386A (ja) 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
EE05450B1 (et) 2000-07-19 2011-08-15 Warner-Lambert Company 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine
AR038972A1 (es) 2002-03-13 2005-02-02 Array Biopharma Inc Derivados de bencimidazol n3 alquilado como inhibidores de mek
PL401638A1 (pl) 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
GB0316232D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316237D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
WO2005009975A2 (en) * 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazole derivatives as mek inhibitors
SI1663242T1 (sl) 2003-08-07 2011-09-30 Rigel Pharmaceuticals Inc 2,4-pirimidindiaminske spojine in uporabe kot antiproliferativna sredstva
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
JP4768628B2 (ja) 2003-11-19 2011-09-07 アレイ バイオファーマ、インコーポレイテッド Ｍｅｋの二環系阻害剤及びその使用方法
WO2005054176A1 (en) 2003-11-25 2005-06-16 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
EP1694663A1 (en) 2003-12-19 2006-08-30 Biovitrum Aktiebolag Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder
ES2338060T3 (es) 2003-12-22 2010-05-03 Basilea Pharmaceutica Ag Componentes de tipo ariloxi y ariltoxia-cetofenona para el tratamiento del cancer.
MXPA06007213A (es) 2003-12-23 2006-08-18 Pfizer Prod Inc Combinacion terapeutica para la mejora de la cognicion y trastornos sicoticos.
AU2006284751A1 (en) 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
HRP20110498T1 (hr) 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
CA2662285A1 (en) 2006-08-31 2008-03-06 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof

Also Published As

Publication number Publication date
CN102137843A (zh) 2011-07-27
CA2727252A1 (en) 2010-01-07
CL2010001637A1 (es) 2011-07-15
MX2010014565A (es) 2011-03-04
KR20110028376A (ko) 2011-03-17
JP2011526924A (ja) 2011-10-20
EP2307364B1 (en) 2013-06-19
WO2010003022A1 (en) 2010-01-07
RU2495028C2 (ru) 2013-10-10
BRPI0910200A2 (pt) 2015-09-29
WO2010003022A8 (en) 2010-09-30
EP2307364A1 (en) 2011-04-13
ZA201008962B (en) 2012-03-28
JP5615274B2 (ja) 2014-10-29
US20110124622A1 (en) 2011-05-26
AU2009266953A2 (en) 2011-01-27
AU2009266953A1 (en) 2010-01-07
US8492427B2 (en) 2013-07-23
RU2011103434A (ru) 2012-08-10
PE20110424A1 (es) 2011-07-22
ES2426096T3 (es) 2013-10-21

Similar Documents

Publication Publication Date Title
ZA201008962B (en) Isoindolone derivatives as mek kinase inhibitors and methods of use
IL210363A0 (en) Kinase inhibitors and methods of use
EP2252293A4 (en) KINASEHEMMER AND USE PROCESS
IL240771A0 (en) Benzoxazole kinase inhibitors and methods of use
ZA201104467B (en) Heterocyclic compounds and methods of use
IL211549A0 (en) Aminotriazolopyridines and their use as kinase inhibitors
ZA201006128B (en) Pim kinase inhibitors and methods of their use
ZA201001051B (en) Benzylbenzene derivatives and methods of use
EP2445885A4 (en) SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CHINESE INHIBITORS AND METHOD FOR THEIR USE
PL2252597T3 (pl) Pochodne pirazyny i ich zastosowanie jako inhibitorów kinaz białkowych
IL212755A0 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
IL206704A0 (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
IL219646A0 (en) Novelnaphthyridine derivatives and the use thereof as kinase inhibitors
PL2101759T3 (pl) Sposoby stosowania inhibitorów MEK
IL208719A0 (en) Inhibitors of protein kinases
ZA201104463B (en) Compounds and methods of use
EP2340244A4 (en) COMPOUNDS AND APPLICATION PROCEDURES
IL216411A0 (en) Pyrazolopyrimidines and related heterocycles as kinase inhibitors
IL209548A0 (en) Diazacarbazoles and methods of use
EP2139891A4 (en) 4-SUBSTITUTED AZAADAMANTANE DERIVATIVES AND METHODS OF USE
IL219935A0 (en) Small pyrimidine derivatives and methods of use thereof
HK1149753A (en) Pim kinase inhibitors and methods of their use
HK1160021A (en) Telomerase inhibitors and methods of use thereof
ZA201002885B (en) Quinoline derivatives and their use as tyrosine kinase inhibitors
GB0805693D0 (en) Combinations of P13-delta and P13-gamma kinase inhibitor compounds